Take over charity assistance to Junshi Bio-Treplimumab National Medical Insurance Implementation

Recently, at the melanoma branch of the second CSCO-Junshi Bio-Tumor Immunity Summit Forum, the anti-PD-1 monoclonal antibody drug Teriplizumab Injection (Tuoyi®) "Yilu is accompanied by Bethune·Tuoyi" The charity donation project" successfully completed its mission and the melanoma indications were included in the national medical insurance catalogue to celebrate the landing ceremony.

Melanoma is known as the "king of cancer".

At the end of 2020, Teriplizumab passed the national medical insurance negotiations and became the only anti-PD-1 monoclonal antibody used for the treatment of melanoma in the new version of the catalog.

Professor Guo Jun, deputy dean of Peking University Cancer Hospital, believes that tumor immunotherapy represented by anti-PD-1 monoclonal antibody has become a cornerstone drug for melanoma patients.

Teriplizumab is the first domestic monoclonal antibody drug targeting PD-1 approved for marketing in China.

Taking into account the financial situation of some patients who are still unable to afford medication, in February 2019, with the support of Junshi Bio, Beijing Bethune Charity Foundation launched the "Benefit Road-Bethune·Tuoyi Charity Donation Project" to relieve patients and The financial burden of his family allows more patients to receive timely treatment.

Shi Yuanyuan, deputy secretary-general of Beijing Bethune Charity Foundation, fully affirmed Junshi Biology’s continuous improvement of the availability of high-quality innovative drugs to benefit patients, and active implementation of corporate social responsibility, and awarded Junshi Biology the "Yilu" Accompanied-Bethune · Tuoyi Public Welfare Donation Project Caring Donation Enterprise" award.

It is understood that after teriplizumab (Tuoyi®) is successfully included in the national medical insurance, it will take over the "Yilu Companion—Bethune·Tuoyi Public Welfare Donation Project", which will reduce the financial burden of patients to a greater extent and help the drug to be available.

About Teriprolizumab Injection (Tuoyi®)

As the first domestically-made monoclonal antibody drug targeting PD-1 that was approved for marketing in my country, Teriprizumab Injection (Tuoyi®) has won the support of a major national science and technology project.

In May 2020, Tuoyi®'s new indications for the treatment of patients with locally advanced or metastatic urothelial cancer who had failed or intolerated systemic treatments were accepted by the National Medical Products Administration (NMPA).